Curis (CRIS) Other Non-Current Liabilities (2010 - 2026)
Curis' (CRIS) quarterly Other Non-Current Liabilities came in at $1.9 million in Q1 2026, down 92.25% YoY from $24.5 million in Q1 2025, and down 91.25% on a QoQ basis from $21.7 million in Q3 2025.
Curis (CRIS) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 92.25% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 92.25% YoY) and the FY2024 annual result came in at $26.6 million, down 21.95% from the prior year.
- Other Non-Current Liabilities slipped to $1.9 million in Q1 2026, from $21.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $52.1 million in Q1 2022 to a low of $1.9 million in Q1 2026.
- A 5-year average of $34.7 million and a median of $32.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities fell 8.23% — and 2026, when it sank 92.25%.
- Tracing CRIS's Other Non-Current Liabilities over 5 years: stood at $43.2 million in 2022, then decreased by 21.11% to $34.1 million in 2023, then fell by 21.95% to $26.6 million in 2024, then slipped by 18.55% to $21.7 million in 2025, then sank by 91.25% to $1.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.9 million (Q1 2026), $21.7 million (Q3 2025), and $22.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Sep 30, 2025 | 21.68 Mn |
| Jun 30, 2025 | 22.80 Mn |
| Mar 31, 2025 | 24.48 Mn |
| Dec 31, 2024 | 26.62 Mn |
| Sep 30, 2024 | 27.21 Mn |
| Jun 30, 2024 | 29.43 Mn |
| Mar 31, 2024 | 31.33 Mn |
| Dec 31, 2023 | 34.10 Mn |
| Sep 30, 2023 | 44.85 Mn |
| Jun 30, 2023 | 46.24 Mn |
| Mar 31, 2023 | 47.39 Mn |
| Dec 31, 2022 | 43.23 Mn |
| Sep 30, 2022 | 50.27 Mn |
| Jun 30, 2022 | 51.25 Mn |
| Mar 31, 2022 | 52.13 Mn |
| Dec 31, 2021 | 53.80 Mn |
| Sep 30, 2021 | 55.17 Mn |
| Jun 30, 2021 | 56.14 Mn |
| Mar 31, 2021 | 56.81 Mn |